Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adela Cañete

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
Expert Opinion on Pharmacotherapy|December 19, 2003
A comparison of current neuroblastoma chemotherapeuticsVictoria Castel, Adela Cañete
Expert Opinion on Emerging Drugs|March 4, 2017
Advances in emerging drugs for the treatment of neuroblastomaPablo Berlanga, Adela Cañete, Victoria Castel
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 16, 2010
Treatment of high-risk neuroblastoma with anti-GD2 antibodiesVictoria Castel, Vanessa Segura, Adela Cañete
Anales De Pediatria (Barcelona, Spain : 2003)|April 13, 2016
[Medulloblastoma: improved survival in recent decades. Unicentric experience]Lucía Igual Estellés, Pablo Berlanga Charriel, Adela Cañete Nieto
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 19, 2005
[Neuroblastoma]Victoria Castel, Adela Cañete, Rosa Noguera, et al.
Histopathology|June 15, 2011
Prognostic value of partial genetic instability in neuroblastoma with ≤50% neuroblastic cell contentMarta Piqueras, Samuel Navarro, Adela Cañete, et al.
Anales De Pediatria|April 19, 2020
[Cancer in the first 18 months of life]Andrea Urtasun Erburu, Maria José Herrero Cervera, Adela Cañete Nieto
Anales De Pediatria|April 22, 2018
[Li-Fraumeni: Will the detection in families increase the survival of its members?]Pablo Gargallo, Vanessa Segura, Yania Yáñez, et al.
BMC Cancer|May 24, 2019
Vitronectin as a molecular player of the tumor microenvironment in neuroblastomaRebeca Burgos-Panadero, Inmaculada Noguera, Adela Cañete, et al.
Pediatric Blood & Cancer|June 11, 2021
Staging childhood cancers in Europe: Application of the Toronto stage principles for neuroblastoma and Wilms tumour. The JARC pilot studyGemma Gatta, Laura Botta, Riccardo Capocaccia, et al.
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
Expert Opinion on Pharmacotherapy|December 19, 2003
A comparison of current neuroblastoma chemotherapeuticsVictoria Castel, Adela Cañete
Expert Opinion on Emerging Drugs|March 4, 2017
Advances in emerging drugs for the treatment of neuroblastomaPablo Berlanga, Adela Cañete, Victoria Castel
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 16, 2010
Treatment of high-risk neuroblastoma with anti-GD2 antibodiesVictoria Castel, Vanessa Segura, Adela Cañete
Anales De Pediatria (Barcelona, Spain : 2003)|April 13, 2016
[Medulloblastoma: improved survival in recent decades. Unicentric experience]Lucía Igual Estellés, Pablo Berlanga Charriel, Adela Cañete Nieto
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 19, 2005
[Neuroblastoma]Victoria Castel, Adela Cañete, Rosa Noguera, et al.
Histopathology|June 15, 2011
Prognostic value of partial genetic instability in neuroblastoma with ≤50% neuroblastic cell contentMarta Piqueras, Samuel Navarro, Adela Cañete, et al.
Anales De Pediatria|April 19, 2020
[Cancer in the first 18 months of life]Andrea Urtasun Erburu, Maria José Herrero Cervera, Adela Cañete Nieto
Anales De Pediatria|April 22, 2018
[Li-Fraumeni: Will the detection in families increase the survival of its members?]Pablo Gargallo, Vanessa Segura, Yania Yáñez, et al.
BMC Cancer|May 24, 2019
Vitronectin as a molecular player of the tumor microenvironment in neuroblastomaRebeca Burgos-Panadero, Inmaculada Noguera, Adela Cañete, et al.
Pediatric Blood & Cancer|June 11, 2021
Staging childhood cancers in Europe: Application of the Toronto stage principles for neuroblastoma and Wilms tumour. The JARC pilot studyGemma Gatta, Laura Botta, Riccardo Capocaccia, et al.
Pageof 12